A phase Ib, pharmacokinetic multiple center, open label study evaluating the safety and efficacy of mycograb [anti-hsp90 monoclonal antibody] administered IV [intravenously] in combination with docetaxel in metastatic or recurrent breast cancer patients

Trial Profile

A phase Ib, pharmacokinetic multiple center, open label study evaluating the safety and efficacy of mycograb [anti-hsp90 monoclonal antibody] administered IV [intravenously] in combination with docetaxel in metastatic or recurrent breast cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2005

At a glance

  • Drugs Docetaxel; Efungumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NeuTec Pharma
  • Most Recent Events

    • 28 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top